<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571192</url>
  </required_header>
  <id_info>
    <org_study_id>SHP626-102</org_study_id>
    <nct_id>NCT02571192</nct_id>
  </id_info>
  <brief_title>A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose</brief_title>
  <official_title>A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how SHP626 is absorbed and excreted from the body
      in healthy males.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters will be determined from the plasma and blood concentration time data of total radioactivity and from the plasma concentration-time data for SHP626 by non-compartmental analysis.</measure>
    <time_frame>Day 1 to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity (RAD) in whole blood and plasma</measure>
    <time_frame>Day 1 to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the total RAD in urine and feces.</measure>
    <time_frame>Day 1 to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of 50mg [14C]-SHP626 and RAD occurring at time of maximum observed concentration (tmax)</measure>
    <time_frame>Day 1 to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration curve (AUC0-t) of 50mg [14C]-SHP626 and RAD from the time of dosing to the last measurable concentration</measure>
    <time_frame>Day 1 to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration curve (AUC0-∞ ) of 50mg [14C]-SHP626 and RAD extrapolated to infinity, calculated using the observed value of the last non-zero plasma concentration</measure>
    <time_frame>Day 1 to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>First order rate constant associated with the terminal portion of the plasma curve terminal half-life (t½) for 50mg [14C]-SHP626 and RAD</measure>
    <time_frame>Day 1 to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CL/F ) of 50mg [14C]-SHP626 and RAD for extravascular administration divided by the fraction of dose absorbed</measure>
    <time_frame>Day 1-10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz/F ) of 50mg [14C]-SHP626 and RAD associated with the terminal slope following extra-vascular administration divided by the fraction of dose absorbed</measure>
    <time_frame>Day 1-10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative amount (Aef )of RAD recovered in stool over the dosing interval</measure>
    <time_frame>Day 1-10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Excreted Percent of RAD recovered in stool over the dosing interval</measure>
    <time_frame>Day 1-10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative amount (Aeu ) of RAD recovered in urine over the dosing interval</measure>
    <time_frame>Day 1-10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Excreted Percent of RAD recovered in urine over the dosing interval</measure>
    <time_frame>Day 1-10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLR ) of 50mg [14C]-SHP626</measure>
    <time_frame>Day 1 -10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize and identify metabolites of [14C]-SHP626 in plasma by accelerator mass spectrometry for radioactivity quantification</measure>
    <time_frame>Day 1 to day 10</time_frame>
    <description>Metabolites in the excreta and/or plasma will then be structurally identified by a combination of techniques such as co-chromatography with authentic reference standards, high performance liquid chromatography-mass spectrometry, and other spectroscopic techniques if necessary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize and identify metabolites of [14C]-SHP626 in urine by accelerator mass spectrometry for radioactivity quantification</measure>
    <time_frame>Day 1 to day 10</time_frame>
    <description>Metabolites in the excreta and/or plasma will then be structurally identified by a combination of techniques such as co-chromatography with authentic reference standards, high performance liquid chromatography-mass spectrometry, and other spectroscopic techniques if necessary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize and identify metabolites of [14C]-SHP626 in feces by liquid scintillation counting</measure>
    <time_frame>Day 1 to day 10</time_frame>
    <description>Metabolites in the excreta and/or plasma will then be structurally identified by a combination of techniques such as co-chromatography with authentic reference standards, high performance liquid chromatography-mass spectrometry, and other spectroscopic techniques if necessary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the safety and tolerability of [14C]-SHP626 by adverse events (AEs) defined as changes, including changes from baseline in physical examination findings</measure>
    <time_frame>Screening to day 7</time_frame>
    <description>AEs will be coded using the agreed upon version of MedDRA. The number of events, incidence, and percentage of TEAEs will be calculated overall, by system organ class and by preferred term. TEAEs will be further summarized by severity and relationship to investigational product. AEs related to investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly summarized/listed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in vital signs</measure>
    <time_frame>Screening to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in ECGs</measure>
    <time_frame>Screening to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in hematology</measure>
    <time_frame>Screening to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in coagulation</measure>
    <time_frame>Screening to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in baseline in urinalysis</measure>
    <time_frame>Screening to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in baseline in chemistry</measure>
    <time_frame>Screening to day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Non-Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Experimental Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose radiolabelled 50mg of SHP626</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP626</intervention_name>
    <description>single oral dose 50mg SHP626 with approximately 5.95 μCi RAD</description>
    <arm_group_label>Experimental Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>5.95 μCi RAD</intervention_name>
    <arm_group_label>Experimental Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 50 years, inclusive, at the time of consent.

          2. Must be considered healthy. Healthy status is defined by absence of evidence of any
             active or chronic disease following a detailed medical and surgical history, a
             complete physical examination including vital signs, 12-lead ECG, hematology, thyroid
             panel (includes T3, T4 and TSH at Screening only), blood chemistry, coagulation and
             urinalysis

          3. Must have a body mass index between 18.0-30.0kg/m² inclusive with a body weight &gt;50 kg
             (110 lbs).

          4. Ability to swallow all investigational product.

          5. A minimum of 1 bowel movement per day.

        Exclusion Criteria:

          1. History of any hematological, hepatic, respiratory, cardiovascular, renal,
             neurological or psychiatric disease, gallbladder removal, gastric bypass surgery,
             ileal resection, any small intestinal resection,or current or recurrent disease that
             could affect the action, absorption, or disposition of the investigational product, or
             clinical or laboratory assessments.

          2. Current or relevant history of physical or psychiatric illness.

          3. Known or suspected intolerance or hypersensitivity to the investigational product, or
             closely-related compounds, or any of the stated ingredients.

          4. Significant illness, as judged by the investigator, within 2 weeks of the dose of
             investigational product.

          5. Known history of alcohol or other substance abuse within the last year.

          6. Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to
             the dose of investigational product.

          7. Within 30 days prior to the dose of investigational product:

               -  Have used an investigational product (if elimination half-life is &lt;6 days,
                  otherwise 5 half-lives).

               -  Have been enrolled in a clinical study (including vaccine studies) that, in the
                  investigator's opinion, may impact this Shire-sponsored study.

               -  Have had any substantial changes in eating habits, as assessed by the
                  investigator.

          8. Confirmed systolic blood pressure &gt;139mmHg or &lt;89mmHg, and diastolic blood pressure
             &gt;89mmHg or &lt;49mmHg.

          9. Twelve-lead ECG demonstrating QTc &gt;450 msec at screening. If QTc exceeds 450msec, the
             ECG should be repeated 2 more times and the average of the 3 QTc values should be used
             to determine the subject's eligibility.

         10. A positive screen for drugs of abuse at Screening or a positive screen for alcohol or
             drugs of abuse at Check-in (Day -1).

         11. Male subjects who consume more than 21 units of alcohol per week or 3 units of alcohol
             per day.

         12. A positive human immunodeficiency virus antibody screen, hepatitis B surface antigen,
             or hepatitis C virus antibody screen.

         13. Use of tobacco in any form

         14. Routine consumption of more than 2 units of caffeine per day

         15. Current use of any medication including over-the-counter, herbal, or homeopathic
             preparations

         16. An inability to follow a standardized diet and meal schedule or inability to fast

         17. Have participated in a [14C]-study within the last 6 months prior to the dose of
             investigational product.

         18. Exposure to clinically significant radiation within 12 months prior to the dose of
             investigational product
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Siebers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Madison Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADME</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 13, 2016</submitted>
    <returned>December 7, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

